Eli Lilly reduces Zepbound weight-loss drug prices amid industry trend
TL;DR Summary
Eli Lilly has reduced the cash prices of its Zepbound weight loss drug vials on its direct-to-consumer platform, making the medication more accessible amid industry price cuts and government efforts to lower drug costs. Starting at $299 per month for the initial dose, the prices are now more affordable compared to the previous $349, aiming to improve access for patients facing high list prices and limited insurance coverage.
- Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site CNBC
- Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company Eli Lilly and Company
- Eli Lilly cuts price for popular weight-loss drug Zepbound USA Today
- Weight-Loss Drug Zepbound Cost Drops To $299 A Month After Trump Deal Forbes
- Lilly joins Novo in GLP-1 self-pay price cuts, lowering costs of single-dose Zepbound vials Fierce Pharma
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
86%
471 → 68 words
Want the full story? Read the original article
Read on CNBC